Trikafta Can't Wait
With compelling research at hand and Canadian CF clinicians behind you, help Canadians living with cystic fibrosis get access to the life-changing drug Trikafta by taking two easy actions today:
ACTION 1: Write a letter to the editor
Use the form below to write a letter to the editor of your local newspaper.
ACTION 2: Write your MP
Use the form below and join more than 5,000 people who have sent letters to their members of parliament.
WHY YOUR ACTIONS ARE NEEDED
Canadians with cystic fibrosis are still waiting for access to Trikafta, a life-saving breakthrough drug that has the potential to treat 90% of the people living with cystic fibrosis. Places around the world including the United States, the UK and Europe have fast-tracked access to Trikafta.
A new, game-changing study has shown the dramatic life-saving benefits of Trikafta. This Canadian research demonstrates that access to Trikafta in 2021 would result in profound health improvements by 2030 for people who take the drug.
By 2030 Trikafta could reduce the number of people living with severe lung disease by 60% and reduce the number of deaths by 15%. The estimated median age of survival for a child born with CF today would increase by 9.2 years. For more information on the research click here.
This research is so compelling that Canadian cystic fibrosis clinicians are raising their voices alongside the cystic fibrosis community to loudly and publicly question: Canada, what are you waiting for? More than 50 Canadian cystic fibrosis clinicians have published an open letter addressed to all levels of government, echoing our urgent calls for access to Trikafta.
For more information on further ways you can help Cystic Fibrosis Canada advocate for fast and fair access to CF drugs please visit our How to Take Action page.
DELAYS HOLDING UP ACCESS TO TRIKAFTA
The Patented Medicine Prices Review Board (PMPRB) has proposed regulatory guidelines that are impacting access to life-changing CF medicines, especially the break-through drug Trikafta.
Cystic Fibrosis Canada’s position on the newly amended PMPRB guidelines is that there are some provisions that could enable access to Trikafta, however the guidelines are still troubling as they go too far. The first section, changing the basket of comparator countries, does the job of reducing prices. Any additional changes will undermine access to innovative medications and need to stop. Cystic Fibrosis Canada submitted a response to the revised draft guidelines on July 28, 2020.
For more information on the proposed changes to the PMPRB and the impact these changes are having on access to life-changing medicines in Canada, like Trikafta, please visit our PMPRB page.